# Safety and Efficacy of Corneal Collagen Cross-linking Following LASIK for Treatment of Hyperopia and Hyperopic Astigmatism

> **NCT01893359** · PHASE1,PHASE2 · TERMINATED · sponsor: **Glaukos Corporation** · enrollment: 2 (actual)

## Conditions studied

- Hyperopia
- Hyperopic Astigmatism

## Interventions

- **DRUG:** riboflavin ophthalmic solution, 0% dextran
- **DEVICE:** UVA Irradiation (30 mW/cm2 for 2 minutes continuous UVA)
- **DEVICE:** UVA Irradiation (30 mW/cm2 for 3 minutes pulsed UVA with an on/off cycle of 2 seconds UVA on/1 second UVA off)
- **PROCEDURE:** Laser-assisted in situ keratomileusis

## Key facts

- **NCT ID:** NCT01893359
- **Lead sponsor:** Glaukos Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-08
- **Primary completion:** 2015-02
- **Final completion:** 2016-04
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2021-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01893359

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01893359, "Safety and Efficacy of Corneal Collagen Cross-linking Following LASIK for Treatment of Hyperopia and Hyperopic Astigmatism". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01893359. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*